Loading...
•
Sep 30, 2020
Exact Sciences Q3 2020 Earnings Report
Generated revenue of $408.4 million, marking a strong quarter with significant progress towards the company's vision.
Key Takeaways
Exact Sciences Corp. announced strong Q3 2020 results, with revenue reaching $408.4 million, compared to $218.8 million in Q3 2019. The company saw growth in Precision Oncology and COVID-19 testing, while also managing an intangible asset impairment charge. They are confident in the long-term growth outlook for Cologuard and Oncotype DX and are excited about the liquid biopsy tests pipeline.
Total revenue was $408.4 million, compared to $218.8 million for the same period of 2019.
Screening revenue was $214.6 million, a decrease of 2 percent.
Precision Oncology revenue was $91.6 million.
COVID-19 testing revenue was $102.2 million.
Revenue by Segment
Forward Guidance
No specific forward guidance was provided in this earnings report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...